Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Clinical trial NCT01170338 · UNKNOWN
Trial details
- NCT number
- NCT01170338
- Sponsor
- Newark Beth Israel Medical Center
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2008-01-01
- Primary completion
- 2011-07-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.